â– LECTURE OVERVIEW: Polycystic Ovary Syndrome (PCOS, Stein-Leventhal syndrome) is a metabolic-endocrine disorder and a leading cause of female infertility.
â– ENDOCRINE PATHWAY DETAIL:
1. Hyperinsulinemia: The primary driver is marked insulin resistance. Hyperinsulinemia suppresses hepatic synthesis of Sex Hormone-Binding Globulin (SHBG).
2. Free Testosterone Surge: Lower SHBG increases circulating free testosterone, driving clinical hyperandrogenism.
3. LH Excess: Pulsatile GnRH release favors the synthesis of Luteinizing Hormone (LH) over Follicle-Stimulating Hormone (FSH), elevating the LH:FSH ratio above 2.
4. Androgen Production: Excess LH stimulates ovarian Theca cells to produce androstenedione. Decreased relative FSH impairs granulosa cell aromatase activity, preventing conversion to estrogens.
5. Anovulation: Follicle maturation halts midway, presenting on ultrasound as multiple subcortical cysts (the 'string of pearls' appearance).
â– THERAPEUTIC TARGETS & MANAGEMENT:
Primary pharmacological intervention aims to restore physiological homeostatic balance. This is achieved by either competitively blocking receptor sites, allosterically inhibiting enzymes, or supplementing missing metabolic products.
â– GENOMIC VARIANT CHARACTERISTICS:
Molecular profiling indicates that specific genetic subtypes exhibit varying levels of enzyme activity and drug-clearance efficiency.
[HY-BOARD-1104]
🌟 Dynamic Clinical Key:
PCOS is diagnosed using the Rotterdam criteria, requiring 2 of 3 features: clinical/biochemical hyperandrogenism (hirsutism, acne), ovulatory dysfunction (oligomenorrhea), or polycystic ovaries on ultrasound. It is associated with a high risk of endometrial hyperplasia and cancer due to unopposed estrogen. Absolute contraindications include pregnancy, renal insufficiency, or concurrent use of metabolic inhibitors. Genetic screening profiles can help tailor precise therapeutic doses for optimal patient outcomes.